Evofem Biosciences second amendment to merger with Aditxt extends loan deadline to Feb 29, proxy filing to Apr 1

Evofem Biosciences, Inc.

Second Amendment to Merger Agreement dated January 30, 2024 extends Parent loan deadline from Jan 31 to Feb 29, 2024.
Company's termination right for failure to receive loan also extended to Feb 29, 2024.
Joint proxy statement filing deadline moved from Jan 31 to April 1, 2024.
No other material changes; all other terms of Merger Agreement remain in full force and effect.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Evofem Biosciences, Inc. amended Second Amendment to the Agreement and Plan of Merger with Aditxt, Inc. valued at amendment to change the date of the Parent Loan to February 29, 2024, termination date for failure t (effective 2024-01-30).

Action: amendment
Agreement: merger
Counterparty: Aditxt, Inc.
Value: amendment to change the date of the Parent Loan to February 29, 2024, termination date for failure t
Effective: 2024-01-30

Exact text from the filing

On January 30, 2024, the Company, Parent and Merger Sub entered into the second amendment to the Merger Agreement (the “Second Amendment”) to amend (i) the date of the Parent Loan (as defined in the Merger Agreement) to the Company to be February 29, 2024, (ii) to change the date by which the Company may terminate the Merger Agreement for failure to receive the Loan from Parent to be February 29, 2024, and (iii) to change the filing date for the Joint Proxy Statement (as defined in the Merger Agreement) to April 1, 2024.

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-004506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.